Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Analysts said consolidation pressure in pharma had not gone away and predicted this would not be the last major merger as drug companies sought efficiency and…
David Graham, Palley-Needelman: executives may be conservatively estimating cost savings at $1.5B annually; any underestimation will drive the price even…
Salomon Brothers analyst Peter Laing: 'Consolidation in the industry hasn’t gone away and the pressure to cut costs hasn’t gone away. I don’t think this will…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
Ciba-Geigy and Sandoz merged in a deal valued at approximately $36.3 billion to create Novartis, the world's second-largest pharmaceutical company at the time. The merger of equals combined two diversified Swiss chemical and pharmaceutical conglomerates.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ciba-Geigy AG / Sandoz AG (this deal) | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| LEO Pharma A/S / AstraZeneca PLC | 2016 | $1.1B | 80 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
← Browse all deals · How we score deals
More: 1996 deals · Dermatology deals